Operations: Vertex Pharmaceuticals generates revenue primarily from its pharmaceutical segment, which amounted to $10.34 billion. The company specializes in therapies for cystic fibrosis (CF).

Vertex Pharmaceuticals' focus on innovative treatments for cystic fibrosis (CF) and acute pain showcases its potential in high-growth tech. Despite a net loss of $3.59 billion in Q2 2024, the company expects product revenues to reach up to $10.85 billion this year, driven by CF therapies and new drug launches like CASGEVY?. Vertex's R&D expenses represent a significant investment in future growth, with notable advancements such as suzetrigine receiving FDA priority review. The company's strategic repurchase of 2.36 million shares for $883.81 million underscores its confidence in long-term prospects.

• Click here and access our complete health analysis report to understand the dynamics of Vertex Pharmaceuticals.

• Gain insights into Vertex Pharmaceuticals' historical performance by reviewing our past performance report.

Zscaler

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zscaler, Inc. operates as a cloud security company worldwide with a market cap of $26.19 billion.

Operations: The company generates revenue primarily through the sale of subscription services to its cloud platform and related support services, amounting to $2.17 billion. The business focuses on providing comprehensive cloud security solutions globally.

Zscaler's recent integration with CrowdStrike Falcon? for advanced threat detection and risk management highlights its innovative approach to cybersecurity. The company's R&D expenses have been substantial, amounting to $340 million in 2024, reflecting a commitment to technological advancement. Despite a net loss of $57.71 million for the year ending July 31, 2024, Zscaler's revenue grew by 34% to $2.17 billion from the previous year. Such investments and partnerships are crucial as software firms increasingly move towards SaaS models, ensuring recurring revenue streams from subscriptions.

• Take a closer look at Zscaler's potential here in our health report.

• Assess Zscaler's past performance with our detailed historical performance reports.

Where To Now?

• Unlock more gems! Our High Growth Tech and AI Stocks screener has unearthed 1272 more companies for you to explore.Click here to unveil our expertly curated list of 1275 High Growth Tech and AI Stocks.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:TTD NasdaqGS:VRTX and NasdaqGS:ZS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]